Related Experiment Video
Updated: May 24, 2026
23:56
Comprehensive & Cost Effective Laboratory Monitoring of HIV/AIDS: an African Role Model
Published on: October 31, 2010
HIV vaccines: an attainable goal?
Lucy Reynell1, Alexandra Trkola
1Institute of Medical Virology, University of Zurich, Switzerland. reynell.lucy@virology.uzh.ch
Swiss Medical Weekly
|March 6, 2012
Summary
Developing an effective human immunodeficiency virus (HIV) vaccine remains challenging. This review examines the difficulties in creating an HIV vaccine that elicits protective immune responses and identifies key obstacles.
Area of Science:
- Immunology
- Vaccinology
- Virology
Background:
- The first large-scale human immunodeficiency virus (HIV) vaccine trial in 2009 offered hope for developing a protective vaccine.
- Despite this progress, significant challenges persist in designing an effective HIV vaccine.
Purpose of the Study:
- To explore the complexities of eliciting protective immune responses against HIV.
- To highlight the major hurdles that must be overcome in HIV vaccine design.
Main Methods:
- Review of existing literature on HIV vaccine research.
- Analysis of immune responses generated in previous vaccine trials.
- Identification of key challenges in HIV vaccine development.
Main Results:
- Eliciting robust and broadly protective immune responses to HIV is a complex immunological challenge.
- Current vaccine strategies face hurdles related to HIV's genetic diversity and immune evasion mechanisms.
Conclusions:
- Achieving a protective HIV vaccine requires overcoming substantial scientific and immunological barriers.
- Further research is essential to address the identified hurdles in HIV vaccine design and development.
Related Concept Videos
01:10Retrovirus Life Cycles
Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...
01:30Cancer Vaccines
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
01:51Vaccinations
Overview
01:21Vaccines
Vaccines are among the most effective tools in preventive medicine, designed to prepare the immune system to recognize and combat infectious agents. By introducing antigens—substances that the immune system identifies as foreign—vaccines stimulate an adaptive immune response that leads to immunological memory. This immunological memory enables the body to mount a faster and more effective response upon future exposures to the actual pathogen.Vaccines can be categorized based on the type of...
01:23Vaccine Production
Vaccine production involves a sequence of upstream and downstream processes to generate a safe and effective immunological product. It begins with cultivating microorganisms, such as viruses or bacteria, to obtain antigenic material. For viral vaccines, mammalian host cells are grown in bioreactors and subsequently infected with the target virus. The virus replicates within the host cells, which are lysed to release viral particles. This lysate is then clarified through filtration or...